Share This Page
Share This Page
The Society for Maternal-Fetal Medicine recently issued its first-ever recommendations for pregnant women with hepatitis C — a segment of population that data suggest impacts 4% of pregnant women in the United States.
“Hepatitis C is an important public health concern for pregnant women,” Brenna L. Hughes, MD, MSc, an author of the recommendations, told Healio Family Medicine.
“We wanted to bring attention to the current recommendations for screening women in pregnancy,” Hughes, who is also the director of the maternal fetal medicine fellowship at the Duke University School of Medicine, continued. “Ideally women can be cured of hepatitis C prior to achieving pregnancy, but for those who come into pregnancy with the infection, we wanted to review and promote best practices.”
FOR IMMEDIATE RELEASE
Contact: Caryn Benisch | 202.429.4940 | email@example.com
NVHR Welcomes FDA Approval of New Hepatitis B Vaccine
FDA Today Approved HEPLISAV-B, the First Hepatitis B Vaccine Approved in the U.S. in Over 25 Years; New Tool Can Help the U.S. Eliminate the Virus & Address the Opioid Epidemic
SAN FRANCISCO, CA (Nov. 9, 2017) – The National Viral Hepatitis Roundtable (NVHR) today welcomed the U.S. Food and Drug Administration’s (FDA) approval of HEPLISAV-B for prevention of hepatitis B virus infection in adults ages 18 and older. HEPLISAV-B is the first new hepatitis B vaccine approved in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
“Today’s approval of HEPLISAV-B provides an important new tool for reversing the unfortunate trend of increased acute hepatitis B infections in the U.S.,” said Ryan Clary, NVHR executive director. “NVHR will work with our advocacy partners to ensure everyone has access to this vaccine, particularly high-risk populations for hepatitis B infection, such as people who inject drugs.”
Hepatitis B is an extremely infectious and potentially deadly virus affecting up to 2 million people in the United States. Asian Americans and Pacific Islanders are disproportionately impacted, accounting for more than 50% of people living with chronic hepatitis B in the country. While there is effective treatment for hepatitis B, there is no cure and infections are on the rise. In 2015, new cases of acute hepatitis B increased by more than 20 percent, largely as a result of the nation’s opioid crisis.
In March 2017, the National Academies of Sciences, Medicine and Engineering released A National Strategy for the Elimination of Hepatitis B and C. The National Academies noted that only a quarter of adults over the age of 19 have been fully immunized against hepatitis B and called for expanded access to vaccination as part of the overall strategy to eliminate the public health threat of hepatitis B in the United States by 2030. Current hepatitis B vaccines require three shots over a six-month period for full protection; however, almost half of adults fail to complete the series within one year. HEPLISAV-B is a two-dose vaccination taken over a one-month period, increasing the likelihood of successful completion.
“Not only is the approval of HEPLISAV-B a significant step towards achieving hepatitis B elimination, but it presents a new opportunity to help end the rapid spread of the virus among people who inject drugs,” added Clary. “The federal government should eliminate barriers for all Americans who inject drugs to get vaccinated for hepatitis B as part of its overall effort to address the nation’s opioid emergency.”
About the National Viral Hepatitis Roundtable (NVHR)
The National Viral Hepatitis Roundtable is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance. NVHR believes an end to the hepatitis B and C epidemics is within our reach and can be achieved through addressing stigma and health disparities, removing barriers to prevention, care and treatment, and ensuring respect and compassion for all affected communities. For more information, visit www.nvhr.org.
National Viral Hepatitis Roundtable
Share This Page
New research shows treatment of hepatitis C (HCV) in the US continues to be hampered by a major lack of public and patient awareness.
The World Hepatitis Alliance unveiled new research last week, showing that just 55% of the 2.7 million people believed to be living with HCV in the US are aware that they are infected with the virus.
At that rate, the alliance said it is unlikely the US will reach its own targets for HCV reduction by 2020.
Depression is an extrahepatic manifestation (EH) of hepatitis C. Add to this EH two potentially life-threatening diseases. It’s no wonder that people living with HIV and hepatitis coinfection are at greater risk for depression than people with HIV, hepatitis C alone or the general public. This simple fact sheet has basic information to help educate patients and providers about this disease. To access this fact sheet, click here.
Patients with hepatitis C virus (HCV) infection achieved the same rates of sustained virologic response (SVR) regardless of whether they were treated by a specialist or non-specialist, in the first prospective trial comparing HCV treatment outcomes by provider in a real-world cohort.
Sarah Kattakuzhy, MD, Clinical and Administrative Director of the DC PFAP Hepatitis Clinical Research Program, and Assistant Professor of Institute of Human Virology in the Division of Infectious Diseases at the University of Maryland, and lead author of the study explained how their findings could support an expansion of HCV treatment.
“Patients are often reticent to see additional providers, and specialist-based treatment may incur additional cost, travel, and/or wait time, particularly in medically underserved areas,” Kattakuzhy told MD Magazine. “Non-specialist based HCV therapy could help close existing gaps in the HCV care cascade, bringing more patients to treatment and cure.”